Jiangsu Hengrui Pharmaceuticals Co Ltd Class A 600276
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
-
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
-
Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up
-
Hengrui Pharma Signs Milestone Drug-Development Deal With GSK
Trading Information
- Previous Close Price
- CN¥53.76
- Day Range
- CN¥52.20–53.75
- 52-Week Range
- CN¥45.26–74.04
- Bid/Ask
- CN¥52.62 / CN¥52.63
- Shares Outstanding
- 6.64B
- Market Cap
- CN¥349.25B
- Volume/Avg
- 87M / 94M
Key Statistics
- Price/Earnings (Normalized)
- 42.46
- Price/Sales
- 10.75
- Dividend Yield (Trailing)
- 0.38%
- Dividend Yield (Forward)
- 0.38%
- Total Yield
- 0.38%
Company Profile
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 20,602
- Website
- https://www.hengrui.com
Valuation
|
Metric
|
600276
|
|---|---|
Price/Earnings (Normalized) | 42.46 |
Price/Book Value | 5.49 |
Price/Sales | 10.75 |
Price/Cash Flow | 30.52 |
Price/Earnings
600276
Financial Strength
|
Metric
|
600276
|
|---|---|
Quick Ratio | 8.36 |
Current Ratio | 9.23 |
Interest Coverage | 2,107.20 |
Quick Ratio
600276
Profitability
|
Metric
|
600276
|
|---|---|
Return on Assets (Normalized) | 11.93% |
Return on Equity (Normalized) | 13.32% |
Return on Invested Capital (Normalized) | 11.63% |
Return on Assets
600276
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|DhVc^wnH | LOCK|w!GP | $68B | |||
| Haleon PLC ADR
HLN
| LOCK|PKBG!wh | LOCK|@K | $42B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|Z><jN<h# | LOCK|#lbx | $42B | |||
| Zoetis Inc Class A
ZTS
| LOCK|m>^@!<QV | LOCK|K$c | $30B | |||
| Viatris Inc
VTRS
| LOCK|#Lr&>?@ | LOCK|kw? | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|tyx | LOCK|#Vv | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|SHqyw!h | LOCK|$@ | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|G&&Wctr | LOCK|C>b | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|^RlQD?j | LOCK|s!q% | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|Tz^^yW | LOCK|!zb | $2B |
United States